InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Browse the full record of transactions filed by Castella Maelys, Membre du Conseil. Officer active across 1 companies, notably UCB. Aggregated, 13 disclosures have been logged. The latest transaction was disclosed on 6 November 2025 — Purchase. Regulator: FSMA. The full history is openly available.
Declarations13 total
€43,200200 shares@ €216.000.0001% mcap17.5% of flow
ShareEuronext Brussels
FSMA:ucb-94·
Ideal exit: 3 Aug 2026 (T+270)
€26,520120 shares@ €221.000.0001% mcap10.7% of flow
ShareEuronext Brussels
FSMA:ucb-186·
Ideal exit: 28 Jul 2026 (T+270)
€14,19060 shares@ €236.500.0000% mcap5.7% of flow
ShareEuronext Brussels
FSMA:ucb-193·
Ideal exit: 24 Jul 2026 (T+270)
€22,700100 shares@ €227.000.0001% mcap9.2% of flow
ShareEuronext Brussels
FSMA:ucb-14·
Ideal exit: 25 Jul 2026 (T+270)
€33,600150 shares@ €224.000.0001% mcap13.6% of flow
ShareEuronext Brussels
FSMA:ucb-64·
Ideal exit: 28 Jul 2026 (T+270)
€12,27550 shares@ €245.500.0000% mcap5.0% of flow
ShareEuronext Brussels
FSMA:ucb-36·
Ideal exit: 20 Jul 2026 (T+270)
€12,25050 shares@ €245.000.0000% mcap5.0% of flow
ShareEuronext Brussels
FSMA:ucb-13·
Ideal exit: 21 Jul 2026 (T+270)
€11,65050 shares@ €233.000.0000% mcap4.7% of flow
ShareEuronext Brussels
FSMA:ucb-195·
Ideal exit: 25 Jul 2026 (T+270)
€11,70050 shares@ €234.000.0000% mcap4.7% of flow
ShareEuronext Brussels
FSMA:ucb-65·
Ideal exit: 24 Jul 2026 (T+270)
€17,50070 shares@ €250.000.0000% mcap7.1% of flow
ShareEuronext Brussels
FSMA:ucb-189·
Ideal exit: 14 Jul 2026 (T+270)
€15,30060 shares@ €255.000.0000% mcap6.2% of flow
ShareEuronext Brussels
FSMA:ucb-11·
Ideal exit: 12 Jul 2026 (T+270)
€14,70060 shares@ €245.000.0000% mcap5.9% of flow
ShareEuronext Brussels
FSMA:ucb-88·
Ideal exit: 28 Jun 2026 (T+270)
€11,75050 shares@ €235.000.0000% mcap4.8% of flow
ShareEuronext Brussels
FSMA:ucb·
Ideal exit: 27 Jun 2026 (T+270)
13 of 13 declarations
About Castella Maelys
Maelys Castella is a member of the administrative management at UCB, a global biopharmaceutical company. In her role, she participates in strategic decision-making and oversight of operations, contributing to the company's mission to improve patients' lives. Her expertise in the pharmaceutical sector is a valuable asset for UCB as she strives to meet industry challenges and innovate in the development of new treatments.
